Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics

Enzalutamide, an antiandrogen, is approved for therapy of castration resistant prostate cancer. Clinical applications have shown that approximately 30% of patients acquire resistance after a short period of treatment. However, the molecular mechanisms underlying this resistance is not completely und...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Shiv, Shankar, Eswar, Kalayci, F. Naz Cemre, Mukunda, Amrita, Alassfar, Malek, Singh, Vaibhav, Chan, E. Ricky, MacLennan, Gregory T., Gupta, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765584/
https://www.ncbi.nlm.nih.gov/pubmed/33339129
http://dx.doi.org/10.3390/ijms21249568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765584/
https://www.ncbi.nlm.nih.gov/pubmed/33339129
http://dx.doi.org/10.3390/ijms21249568

Ejemplares similares